Delivery Order SPE2DB25D3003-SPE2DB25FPXEJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a delivery order valued at $8,396.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other inflammatory conditions,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose). This firm fixed-price, competitively awarded contract with no set-aside designation is scheduled for completion by August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used to treat inflammatory and...
- The Defense Logistics Agency awarded a delivery order valued at $29,328.80 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed price, competitively awarded delivery order represents non-set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.63 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis...
- The Defense Logistics Agency (DLA) awarded a $56,308.41 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on July 8, 2025, with an ultimate completion date of July 9, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,154.87 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order was awarded competitively with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a prescription medication used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a $18,491.04 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is a non-set-aside procurement with an ultimate completion date of August 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,198.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-tablet units). This contract was competitively awarded without set-aside provisions under a firm fixed-price structure, with an ultimate completion date of June 20, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. RINVOQ (upadacitinib) is a JAK inhibitor used for treating...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count unit dose packaging) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $11,665.94 and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPXEJDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,406.11 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages). This competitive award, made on September 16, 2025, represents a firm fixed-price delivery order with an ultimate completion date of September 17, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the DLA's ongoing procurement of pharmaceutical products to support military healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen Drug Corp regularly fulfills medical procurement requirements through the DLA's Medical Supply Chain, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through competitively awarded contracts with firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 9/16/25 |